Relationship between monocyte to high-density lipoprotein ratio and contrast-induced nephropathy in patients with non-st elevation myocardial infarction

Year 2020, Volume: 11 Issue: 3, 154 - 160, 22.06.2020

Onur Baydar Alparslan Kılıç

https://doi.org/10.18663/tjcl.637234

Cited By: 1

Abstract

Aim: Contrast-induced nephropathy (CIN) is associated with worse prognosis in patients with non-ST-elevation myocardial infarction (NSTEMI). Early identification patients with a high risk of CIN are very crucial to improve outcomes. The monocyte to high-density lipoprotein ratio (MHR) is a novel inflammatory marker. We aimed to investigate the MHR had a predictive role for CIN development in patients with NSTEMI.
Material and Methods: NSTEMI who underwent percutaneous coronary intervention (PCI) were included in the study. MHR was calculated and CIN was defined as an increase in serum creatinine 25% or 0.5 mg/dl from baseline in the first 48- 72 hours.

Results: A total of 370(200, 54.1% men) patients were included in this study and 104 (28.1%) of them had DM. 25 (6.7%) of patients had CIN. MHR was significantly higher in patients with CIN (0.014± 0.004 vs 0.011± 0.006-respectively, p: 0.017). MHR was also significantly correlated with creatinine levels after PCI (r:0,104, p: 0.047). CIN group also experienced a more complicated in-hospital clinical course. Additionally; weight and MHR were detected as independent risk factors of CIN in logistic regression analysis.
Conclusion: Preprocedural MHR may be used as cheap, easy and simple marker of CIN. It may help with the early identification of patients with NSTEMI who are at high risk of CIN.

Keywords

myocardial infarction, contrast-induced nephropathy, monocyte to high-density lipoprotein ratio

Monosit/yüksek-dansiteli lipoprotein oranının st elevasyonu olmayan miyokard enfarktüslü hastalarda kontrasta bağlı nefropatiyle ilişkisi

Abstract

Amaç: Kontrast madde kullanımına bağlı nefropati (KBN) gelişimi perkutan koroner girişim (PKG) yapılan ST elevasyonu olmayan miyokard enfarktüsü (NON-STEMI) geçiren hastalarda sık görülmekte olup artmış mortalite ve morbidite ile ilişklidir. KBN açısından yüksek riskli hastaların önceden tespiti ve tedavisi, klinik sonuçların iyileşmesinde etkili olacaktır. Monosit yüksek dansiteli lipoprotein (HDL) oranı ( MHO) klinikte yeni tanımlanan inflamasyon belirteçlerinden biridir. Çalışamızda işlem öncesi MHO’ nın PKG yapılmış NON-STMI hastalarında KBN gelişimi arasıdaki ilişki araştırılmıştır.
Gereç ve Yöntemler: Çalışmamızda retrospektif olarak NON-STEMI tanısıyla PKG yapılan hastalar incelenmiştir. Hastaneye başvuruşunda alınan örneklerden MHO oranın hesaplanmış ve KBN; işlemden 48-72 saat sonra bakılan serum kreatininde bazal değere göre % 25 ya da 0,5 mg/dl artış olarak tanımlanmıştır.
Bulgular: Toplam 370 (200, %54.1 erkek ) hasta geriye dönük incelenmiş, 25 (%6.7) hastada KBN geliştiği saptanmıştır. Ayrıca hastaların 104’ünde (%28.1) Diabetes Mellitus (DM) olduğu görülmiştür. MHO; KBN gelilşen grupta gelişmeyen gruba göre anlamlı olarak yüksek saptandı (sırasıyla 0.014± 0.004 ve 0.011± 0.006, p: 0.017). Ek olarak MHO ile PKG sonrası kreatinin değerleri arasında pozitif korelasyon saptandı (r:0,104, p: 0.047). Beklendiği gibi KBN gelişen hastların yatışları sırasında daha çok komplikasyon olduğu görüldü. Ayrıca; kilo ve MHO değerleri KBN gelişimi için bağımsız risk faktörleri olarak bulundu.
Sonuç: MHO ucuz, basit ve kolay şekilde saptanabilen inflamasyon belirteci olup, PKG yapılan NON-STEMI hastlarında KBN’nin saptanmasında ve tedavinin yönlendirilmesinde faydalı olabilir.

Keywords

Miyokard enfarktüsü, Kontrast madde kullanımına bağlı nefropati, monosit yüksek dansiteli lipoprotein oranı

References

• 1. Celik IE, Kurtul A, Duran M et al. Elevated serum fibrinogen levels and risk of contrast-induced acute kidney injury in patients undergoing a percutaneous coronary intervention for the treatment of acute coronary syndrome. Coronary artery disease 2016; 27: 13-8.
• 2. Narula A, Mehran R, Weisz G et al. Contrast-induced acute kidney injury after primary percutaneous coronary intervention: results from the HORIZONS-AMI substudy. European heart journal 2014: ehu063.
• 3. Caixeta A, Mehran R. Evidence‐based management of patients undergoing PCI: Contrast‐induced acute kidney injury. Catheterization and Cardiovascular Interventions 2010; 75: 15-20.
• 4. Balta S, Celik T, Ozturk C, Kaya MG, Aparci M, Yildirim AO et al. The relation between monocyte to HDL ratio and no-reflow phenomenon in the patients with acute ST-segment elevation myocardial infarction. The American journal of emergency medicine 2016; 34: 1542-47.
• 5. Senoo T, Motohiro M, Kamihata H et al. Contrast-induced nephropathy in patients undergoing emergency percutaneous coronary intervention for acute coronary syndrome. The American journal of cardiology 2010; 105: 624-28.
• 6. Mehran R, Aymong ED, Nikolsky E et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. Journal of the American College of Cardiology 2004; 44: 1393-99.
• 7. Ebru AE, Kilic A, Korkmaz FS et al. Is cystatin-C superior to creatinine in the early diagnosis of contrast-induced nephropathy?: a potential new biomarker for an old complication. Journal of postgraduate medicine 2014; 60: 135-40.
• 8. Mehran R, Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney International 2006; 69: 11-15.
• 9. Barrett BJ, Parfrey PS. Preventing nephropathy induced by contrast medium. New England Journal of Medicine 2006; 354: 379-86.
• 10. Goldenberg I, Matetzky S. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. Canadian Medical Association Journal 2005; 172: 1461-71.
• 11. Kurtul A, Murat SN, Yarlioglues M, et al. Procalcitonin as an Early Predictor of Contrast-Induced Acute Kidney Injury in Patients With Acute Coronary Syndromes Who Underwent Percutaneous Coronary Intervention. Angiology 2015; 66: 957-63.
• 12. Liu Y, Tan N, Zhou Y-L, et al. High-sensitivity C-reactive protein predicts contrast-induced nephropathy after primary percutaneous coronary intervention. Journal of nephrology 2012; 25: 332.
• 13. Gao F, Zhou YJ, Zhu X, Wang ZJ, Yang SW, Shen H. C-reactive protein and the risk of contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention. American journal of nephrology 2011; 34: 203-10.
• 14. Cetin MS, Ozcan Cetin EH, Kalender E, et al. Monocyte to HDL cholesterol ratio predicts coronary artery disease severity and future major cardiovascular adverse events in acute coronary syndrome. Heart, lung & circulation 2016; 25: 1077-86.
• 15. Karatas MB, Canga Y, Ozcan KS et al. Monocyte to high-density lipoprotein ratio as a new prognostic marker in patients with STEMI undergoing primary percutaneous coronary intervention. The American journal of emergency medicine 2016; 34: 240-44.
• 16. Canpolat U, Cetin EH, Cetin S et al. Association of monocyte-to-HDL cholesterol ratio with slow coronary flow is linked to systemic inflammation. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2016; 22: 476-82.
• 17. Sag S, Yildiz A, Aydin Kaderli A, Gul BC et al. Association of monocyte to HDL cholesterol level with contrast induced nephropathy in STEMI patients treated with primary PCI. Clinical chemistry and laboratory medicine 2016.
• 18. Lin KY, Zheng WP, Bei WJ et al. A novel risk score model for prediction of contrast-induced nephropathy after emergent percutaneous coronary intervention. Int J Cardiol 2017; 230: 402-12.
• 19. Akcay A, Nguyen Q, Edelstein CL. Mediators of inflammation in acute kidney injury. Mediators Inflamm 2009; 2009: 137072.
• 20. Mestas J, Ley K. Monocyte-endothelial cell interactions in the development of atherosclerosis. Trends Cardiovasc Med 2008; 18: 228-32.
• 21. Woollard KJ, Geissmann F. Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol 2010; 7: 77-86.
• 22. Murphy AJ, Woollard KJ. High-density lipoprotein: a potent inhibitor of inflammation. Clin Exp Pharmacol Physiol 2010; 37: 710-8.
• 23. Mehran R, Aymong ED, Nikolsky E et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004; 44: 1393-99.
• 24. Ando G, Morabito G, de Gregorio C, Trio O, Saporito F, Oreto G. Age, glomerular filtration rate, ejection fraction, and the AGEF score predict contrast-induced nephropathy in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Catheter Cardiovasc Interv 2013; 82: 878-85.
• 25. Ando G, Morabito G, de Gregorio C, Trio O, Saporito F, Oreto G. The ACEF score as predictor of acute kidney injury in patients undergoing primary percutaneous coronary intervention. Int J Cardiol 2013; 168: 4386-87.